ABBV vs GE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and GE Aerospace — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
GE Aerospace · Industrials
$308.35
-44.2% upside to fair value
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GE |
| Current Price |
$208.05 |
$308.35 |
| Fair Value Estimate |
$217.50 |
$171.94 |
| Upside to Fair Value |
+4.5%
|
-44.2%
|
| Market Cap |
$367.9B |
$325.2B |
| Forward P/E |
14.9x
|
37.8x
|
| EV / EBITDA |
16.7x
|
27.9x
|
| Price / Sales |
6.1x
|
7.2x
|
| Price / FCF |
20.9x
|
45.2x
|
| Revenue Growth YoY |
+8.6%
|
+18.5%
|
| Gross Margin |
83.7%
|
36.8%
|
| Operating Margin |
34.7%
|
19.1%
|
| Return on Equity |
-129.24%
|
46.6%
|
| Dividend Yield |
3.2% |
0.44% |
| FCF Yield |
4.78%
|
2.21%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
GE Aerospace is the dominant pure-play aerospace engine company globally, operating through Commercial Engines and Services and Defense and Propulsion Technologies segments. The company delivered 18.5% revenue growth to $45.9 billion in 2025, driven by LEAP engine deliveries, a $190 billion backlog, and robust aftermarket services that generate majority profits. CEO Larry Culp has executed a rema…
Accumulation Zones
| Metric |
ABBV |
GE |
| Zone Low |
$163.13 |
$128.96 |
| Zone High |
$184.88 |
$146.15 |
| In Buy Zone? |
No
|
No
|